Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Annovis Bio Inc.

In a report released today, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Annovis Bio, with a price target of $17.00. According...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ANVS	$4.13	+8.97%	1.04M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ANVS	$4.13	+9.0%	1.04M
3
4
5
6

ANVS

ANVS

Dividend Overview

Get Annovis Bio Inc. Data in Excel

Get Annovis Bio Inc. Data in Excel